

Special Issue

Neoadjuvant Chemoradiotherapy for Gastrointestinal Cancer

Message from the Guest Editor

We are pleased to invite you to a Special Issue of *Cancers* covering neoadjuvant chemoradiotherapy (CRT) for gastrointestinal (GI) cancer, focusing on rectal cancer, esophageal cancer, gastric cancer, and pancreatic cancer. Neoadjuvant CRT has been a cornerstone in the treatment of many GI cancers, aiming for downstaging in order to improve surgical outcome and enhance survival. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but not limited to) the following: clinical trials, novel combinations of systemic therapies, immunotherapy, and radiotherapy, novel strategies for applying radiotherapy in order to minimize toxicities and/or improve treatment results, as well as the role of molecular markers in refining treatment strategies.

Guest Editor

Dr. Daniel Martin

1. Department of Radiotherapy and Oncology, Goethe University Frankfurt, University Hospital, Frankfurt, Germany
2. German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Frankfurt, Germany
3. Frankfurt Cancer Institute (FCI), Goethe University Frankfurt, Frankfurt, Germany

Deadline for manuscript submissions

closed (31 March 2026)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/219449

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)